| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.023 | 0.5 |
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.5 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.5 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | BRD-A71883111 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.5 |
| mRNA | valdecoxib | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | Bexarotene | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |